IVD 패널 검사 시장 : 호흡기/비호흡기(2020-2030년)

The global market for respiratory and non-respiratory IVD panel-based testing is undergoing continued structural evolution. Panel-based tests allow for the simultaneous detection of multiple pathogens and or resistance markers from a single specimen, supporting efficient workflows, faster time to results, and greater diagnostic confidence. Market growth is increasingly driven by broader clinical adoption and expanding use across a range of testing environments.

Kalorama Information analyzes, estimates, and forecasts this market in Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030.

Segment Landscape

Respiratory panels remain an important component of the panel-based testing market, supported by widespread clinical use and recurring seasonal demand. These tests are offered across multiple formats, including molecular, immunoassay, and point-of-care platforms, and represent a meaningful share of overall market revenues.

Non-respiratory panels account for a growing portion of panel-based testing and span a range of applications, including infectious disease and other specialized testing areas. This segment reflects increasing test menu diversity and the integration of panel-based approaches across multiple laboratory settings.

End Users and Care Settings

Demand for panel-based testing is concentrated in hospital and acute care environments, where broad test menus and rapid clinical decision-making are essential. Emergency and urgent care settings contribute significant testing volumes, while additional utilization occurs across other care settings for non-respiratory applications.

Geographic Scope

North America is the largest regional market for respiratory and non-respiratory IVD panel-based testing, supported by a well-established installed base and mature diagnostic infrastructure. Worldwide IVD Panel-Based Testing: Respiratory/Non-Respiratory, 2020-2030 also examines Europe, Asia Pacific, and the Rest of the World to provide a global market perspective.

Scope and Methodology

This report analyzes the global IVD panel-based testing market at the manufacturer level, covering both respiratory and non-respiratory tests across multiple technology categories:

• Molecular
• Immunoassay
• Point-of-care
• Core laboratory
• Anatomic pathology
• Immunohematology

Market data spans 2020 through 2030, with 2025 as the base year and CAGR calculations provided for the 2025 to 2030 forecast period. Regional and end-user analyses are included, with forecasts informed by demographic trends, technological innovation, new product development, and global expansion.

Research findings are based on extensive primary and secondary research, including interviews with industry executives, consultants, healthcare providers, and government personnel, supported by analysis of company materials, databases, investment reports, and medical and business journals.

Table of Contents

Chapter 1: Executive Summary

• About Kalorama Information
• Industry at a Glance
• Scope and Methodology
• Size and Growth of the Market
  • Table 1-1: Total IVD Panel Market, 2020-2030 ($ million)
  • Figure 1-1: Total IVD Panel Market, 2020-2030 ($ million)
• Key Issues and Trends Affecting the Market
• Conclusion Highlights

Chapter 2: Introduction

• Overview
• IVD Clinical Panel Types
  • Infectious Disease Syndromic Panels
  • Targeted Infectious Disease Mini-Panels
  • Antimicrobial Resistance (AMR) Panels
  • Oncology Genomic (NGS) Panels
  • STI Panels
  • Genetic and Inherited Disease Panels
  • Prenatal Panels
  • Issues and Trends
  • Reimbursement for Multiplex Tests
  • IVD Multiplex Regulatory Overview
  • Advantages of Multiplex IVD Testing
  • Clinical Relevance and Over-Testing Challenges

Chapter 3: Molecular IVD Panel-Based Tests

• Introduction
  • Table 3-1: Molecular IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
  • Figure 3-1: Molecular IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue, 2020-2030 ($ million)
  • Figure 3-2: Molecular IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
• End User Market: Molecular IVD Panels
  • Figure 3-3: End User Revenue Source Distribution: Molecular IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
• Respiratory Technology Panels
  • Molecular Respiratory IVD Panel-Based Tests
  • Respiratory Clinical Indication Panels
  • Syndromic Infectious Disease Respiratory Panels
  • Targeted Mini and Combo Respiratory Panels
  • Lab-based Molecular Panel Market
    • Table 3-2: Lab-based Molecular Respiratory IVD Panel-Based Tests, 2025-2030 ($ million)
    • Figure 3-4: Lab-based Molecular Respiratory IVD Panel-Based Tests, 2020-2030 ($ million)
    • Figure 3-5: Lab-based Molecular Respiratory IVD Panel-Based Tests, Distribution by Type, 2025 (%) [Syndromic, Combo/Mini]
• Non-Respiratory Technology Panels
  • Molecular Infectious Disease (Non-Respiratory) Multiplex Panels
    • Table 3-3: Molecular Non-Respiratory Infectious Disease Panel-Based Tests, Overall Market, 2025-2030 ($ million)
    • Figure 3-6: Molecular Non-Respiratory Infectious Disease Panel-Based Tests, by Type, 2020-2030 ($ million) [Blood Bank Screening; Bloodstream Infection, HAI, Sepsis, STI; Hepatitis; Other Infectious Disease]
  • Bloodstream
    • Table 3-4: Molecular Bloodstream Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
  • Sexually Transmitted Infections (STI)
    • Table 3-5: Molecular Sexually Transmitted Infection (STI) Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
  • Hepatitis
    • Table 3-6: Molecular Hepatitis Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
  • Blood Screening
    • Table 3-7: Molecular Blood Screening Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
  • Other
    • Table 3-8: Other Molecular Non-Respiratory Infectious Disease Panel-Based Tests, 2025-2030 ($ million)
  • Molecular and Other Non-Respiratory Panel-Based Tests
    • Table 3-9: Molecular and Other Non-Respiratory IVD Panel-Based Tests, Overall Market, 2025-2030 ($ million)
    • Figure 3-7: Molecular and Other Non-Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Genetic, Oncology, Tissue Typing]
  • Oncology
    • Table 3-10: Molecular Oncology IVD Panel-Based Tests, 2025-2030 ($ million)
  • Genetic
    • Table 3-11: Molecular Genetic IVD Panel-Based Tests, 2025-2030 ($ million)
  • Tissue Typing
    • Table 3-12: Molecular Tissue Typing IVD Panel-Based Tests, 2025-2030 ($ million)
  • Geographic Market Overview
    • Table 3-13: Regional Summary - Molecular IVD Panels, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 3-8: Regional Summary - Molecular IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 4: Immunoassay IVD Panel-Based Tests

• Introduction
  • Table 4-1: Immunoassay IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
  • Figure 4-1: Immunoassay IVD Panel-Based Tests (Respiratory, Non-Respiratory), 2020-2030 ($ million)
  • Figure 4-2: Immunoassay IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
• End User Market: Immunoassay IVD Panels
  • Figure 4-3: End User Revenue Source Distribution, Immunoassay IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
• Respiratory Technology Panels
  • Immunoassay Combo Panels
    • Table 4-2: Immunoassay Respiratory IVD Panel-Based Tests, 2025-2030 ($ million)
    • Figure 4-4: Immunoassay Respiratory IVD Panel-Based Tests, 2020-2030 ($ million)
• Non-Respiratory Technology Panels
  • Immunoassay Non-Respiratory Infectious Disease Multiplex Panels
    • Table 4-3: Immunoassay Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
    • Figure 4-5: Immunoassay Non-Respiratory Infectious Disease IVD Panel-Based Tests, by Type, 2020-2030 ($ million) [Blood Bank Screening; Bloodstream, HAI, Sepsis; Hepatitis; STI; ToRCH; Other]
  • Bloodstream
    • Table 4-4: Bloodstream Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
  • Sexually Transmitted Infections (STI)
    • Table 4-5: Sexually Transmitted Infections (STI) Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
  • Hepatitis
    • Table 4-6: Hepatitis Immunoassay Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
  • ToRCH
    • Table 4-7: ToRCH Infectious Disease IVD Immunoassay Panel-Based Tests, 2025-2030 ($ million)
  • Blood Bank Screening
    • Table 4-8: Blood Bank Infectious Disease Screening Immunoassay IVD Panel-Based Tests, 2025-2030 ($ million)
  • Immunoassay Other Non-Respiratory Disease IVD Multiplex Panels
    • Table 4-9: Immunoassay and Other Non-Respiratory Disease IVD Multiplex Panel-Based Tests, 2025-2030 ($ million)
  • Allergy
    • Table 4-10: Allergy Immunoassay Panel-Based Tests, 2025-2030 ($ million)
  • Autoimmune
    • Table 4-11: Autoimmune Immunoassay Panel-Based Tests, 2025-2030 ($ million)
  • Thyroid
    • Table 4-12: Thyroid Immunoassay Panel-Based Tests, 2025-2030 ($ million)
  • Toxicology and Drugs of Abuse
    • Table 4-13: Toxicology and Drugs of Abuse Immunoassay Panel-Based Tests, 2025-2030 ($ million)
  • Other Immunoassay Panels (Non-Respiratory)
    • Table 4-14: Other Immunoassay Panel-Based Tests, 2025-2030 ($ million)
    • Figure 4-6: Immunoassay Non-Respiratory Other IVD Panel-Based Tests, by Type, 2020-2030 ($ million) [Allergy, Autoimmune, Thyroid, Toxicology/Drugs of Abuse, Other]
  • Geographic Market Overview
    • Table 4-15: Immunoassay Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
    • Figure 4-7: Regional Summary: Immunoassay IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 5: Point-of-Care (POC) IVD Panel-Based Tests

• Introduction
  • Table 5-1: POC IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
  • Figure 5-1: POC IVD Panel-Based Tests, by Segment, 2020-2030 ($ million) [Respiratory, Non-Respiratory]
  • Figure 5-2: POC IVD Panel-Based Tests, Respiratory/Non-Respiratory Revenue Distribution, 2025 (%)
• End User Market: Point-of-Care IVD Panels
  • Figure 5-3: End User Revenue Source Distribution: POC IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, OTC and Retail Settings, Physician Offices]
• Respiratory Technology Panels
  • POC Immunoassay Respiratory Panels
    • Table 5-2: POC Immunoassay Respiratory Panel-Based Tests, 2025-2030 ($ million)
  • POC Molecular Respiratory Panels
    • Table 5-3: POC Molecular Respiratory Panel-Based Tests, 2025-2030 ($ million)
    • Figure 5-4: POC Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Immunoassay/Molecular]
• Non-Respiratory Technology Panels
  • POC Non-Respiratory Infectious Disease Panel-Based Tests
    • Figure 5-5: POC Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2020-2030 ($ million) [Hepatitis, STI, Other]
  • Sexually Transmitted Infections
    • Table 5-4: POC Sexually Transmitted Infection (STI) Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
  • Hepatitis
    • Table 5-5: POC Hepatitis Non-Respiratory Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
  • Other Infectious Diseases
    • Table 5-6: POC Other Infectious Disease IVD Panel-Based Tests, 2025-2030 ($ million)
  • POC Non-Respiratory Other IVD Panel-Based Tests
    • Table 5-7: POC Non-Respiratory Other IVD Panel-Based Tests, 2025-2030 ($ million)
    • Figure 5-6: POC Other Non-Respiratory IVD Panel-Based Tests, 2020-2030 ($ million) [Critical Care, Hematology, Lipid, Tox/Drug of Abuse, Urinalysis, Other]
  • Critical Care
    • Table 5-8: POC Critical Care IVD Panel-Based Tests, 2025-2030 ($ million)
  • Hematology
    • Table 5-9: POC Hematology IVD Panel-Based Tests, 2025-2030 ($ million)
  • Lipid
    • Table 5-10: POC Lipid IVD Panel-Based Tests, 2025-2030 ($ million)
  • Toxicology/Drugs of Abuse
    • Table 5-11: POC Toxicology/Drugs of Abuse IVD Panel-Based Tests, 2025-2030 ($ million)
  • Urinalysis
    • Table 5-12: POC Urinalysis IVD Panel-Based Tests, 2025-2030 ($ million)
  • Other
    • Table 5-13: POC Other IVD Panel-Based Tests, 2025-2030 ($ million)
• Geographic Market Overview
  • Table 5-14: POC IVD Panels, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
  • Figure 5-7: Regional Summary - POC IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 6: Core Laboratory Panel-Based Tests

• Introduction
  • Table 6-1: Core Lab IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
  • Figure 6-1: Core Lab IVD Panel-Based Tests, 2020-2030 ($ million)
• End User Market: Core Lab IVD Panels
  • Figure 6-2: End User Revenue Source Distribution: Core Lab IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, OTC and Retail Settings, Physician Offices]
• General Chemistry IVD Panel-Based Tests
  • Table 6-2: General Chemistry IVD Panel-Based Tests, 2020-2030 ($ million)
  • Figure 6-3: General Chemistry IVD Panel Summary, 2020-2030 ($ million)
• Blood Gases IVD Panel-Based Tests
  • Table 6-3: Blood Gases IVD Panel-Based Tests, 2020-2030 ($ million)
  • Figure 6-4: Blood Gases IVD Panel Summary, 2020-2030 ($ million)
• Urinalysis IVD Panel-Based Tests
  • Table 6-4: Urinalysis IVD Panel-Based Tests, 2020-2030 ($ million)
  • Figure 6-5: Urinalysis IVD Panel Summary, 2020-2030 ($ million)
• Hematology IVD Panel-Based Tests
  • Table 6-5: Hematology IVD Panel-Based Tests, 2020-2030 ($ million)
  • Figure 6-6: Hematology IVD Panel Summary, 2020-2030 ($ million)
• Geographic Market Overview
  • Table 6-6: Core Lab IVD Panels, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
  • Figure 6-7: Regional Summary - Core Lab IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 7: Anatomic Pathology Panel-Based Tests

• Introduction
  • Table 7-1: Anatomic Pathology IVD Panel-Based Tests, Overall Segment Revenue, 2020-2030 ($ million)
  • Figure 7-1: Anatomic Pathology IVD Panel-Based Tests, 2020-2030 ($ million)
• End User Market: Anatomic Pathology IVD Panels
  • Figure 7-2: End User Revenue Source Distribution: Anatomic Pathology IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
• Geographic Market Overview
  • Table 7-2: Anatomic Pathology Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
  • Figure 7-3: Regional Summary - Anatomic Pathology IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 8: Immunohematology Panel-Based Tests

• Introduction
  • Table 8-1: Immunohematology IVD Panel-Based Tests, 2020-2030 ($ million)
  • Figure 8-1: Immunohematology IVD Panel-Based Tests, 2020-2030 ($ million)
• End User Market: Immunohematology IVD Panels
  • Figure 8-2: End User Revenue Source Distribution: Immunohematology IVD Panel-Based Tests, 2025 (%) [Emergency and Acute Care Units, Hospital Laboratories, Independent and Reference Laboratories, Physician Offices]
• Geographic Market Overview
  • Table 8-2: Immunohematology Panel-Based Tests, Geographic Markets, 2025-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
  • Figure 8-3: Regional Summary - Immunohematology IVD Panels, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]

Chapter 9: Market Panel-Based IVD Testing Analysis

• Total Market
  • Table 9-1: Total IVD Panel Market, by Segment, 2020-2030 ($ million) [Anatomic Pathology, Core Laboratory, Immunoassay, Immunohematology, Molecular, Point-of-Care]
  • Figure 9-1: Total Panel-Based IVD Testing Market-Respiratory/Non-Respiratory, 2020-2030 ($ million)
  • Figure 9-2: Total Global Panel-Based IVD Testing Market-Respiratory/Non-Respiratory-Revenue Distribution, 2025 (%)
  • Respiratory IVD Panel-Based Testing Market
    • Table 9-2: Total Respiratory IVD Panel Market, 2020-2030 ($ million) [Immunoassay, Molecular, Point-of-Care]
    • Figure 9-3: Total Respiratory IVD Panel Market, 2020-2030 ($ million) [Immunoassay, Molecular, Point-of-Care]
  • Non-Respiratory Panel-Based IVD Testing Market
    • Table 9-3: Total Non-Respiratory IVD Panel Market, 2020-2030 ($ million)
    • Figure 9-4: Total Non-Respiratory IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
• Market by Target
  • Respiratory
    • Table 9-4: Respiratory IVD Panels, 2020-2030 ($ million)
    • Figure 9-5: Respiratory IVD Panels, 2020-2030 ($ million)
  • Infectious Disease (Non-Respiratory)
    • Table 9-5: Infectious Disease Non-Respiratory Panel-Based Tests, Overall Market, 2025-2030 ($ million)
  • Bloodstream/HAI/Sepsis
    • Table 9-6: Bloodstream/HAI/Sepsis IVD Panels, 2020-2030 ($ million)
    • Figure 9-6: Bloodstream/HAI/Sepsis IVD Panels, 2020-2030 ($ million)
  • Sexually Transmitted Infections
    • Table 9-7: Sexually Transmitted Infection (STI) IVD Panels, 2020-2030 ($ million)
    • Figure 9-7: Sexually Transmitted Infection (STI) IVD Panels, 2020-2030 ($ million)
  • Hepatitis
    • Table 9-8: Hepatitis IVD Panels, 2020-2030 ($ million)
    • Figure 9-8: Hepatitis IVD Panels, 2020-2030 ($ million)
  • Blood Bank Screening
    • Table 9-9: Blood Bank Screening IVD Panels, 2020-2030 ($ million)
    • Figure 9-9: Blood Bank Screening IVD Panels, 2020-2030 ($ million)
  • ToRCH
    • Table 9-10: ToRCH IVD Panels, 2020-2030 ($ million)
    • Figure 9-10: ToRCH IVD Panels, 2020-2030 ($ million)
  • Other (Non-Respiratory) IVD Panel Targets
    • Table 9-11: Other, Non-Respiratory IVD Panel Targets, 20205-2030 ($ million)
    • Table 9-12: Other, Non-Respiratory IVD Panel Targets, by Type, 2025, ($ million) [Allergy, Autoimmune, Blood Gases + Critical Care, Blood Grouping/Typing, Genetic + Prenatal Testing, General Chemistry, Hematology, Immunohistochemistry (IHC), Lipid (Cholesterol), Oncology, Thyroid, Tissue Typing, Toxicology/Drugs of Abuse, Urinalysis, Other]
    • Figure 9-11: Other, Non-Respiratory IVD Panel Targets, by Type, 2025, ($ million) [Allergy, Autoimmune, Blood Gases + Critical Care, Blood Grouping/Typing, Genetic + Prenatal Testing, General Chemistry, Hematology, Immunohistochemistry (IHC), Lipid (Cholesterol), Oncology, Thyroid, Tissue Typing, Toxicology/Drugs of Abuse, Urinalysis, Other]
• Market by End-User Distribution
  • Figure 9-12: Total Global Panel-Based IVD Testing Market, By End User, 2020-2030 ($ million) [Emergency/UC, Hospital, Independent/Reference, OTC/Retail, Physician Office]
  • Figure 9-13: Total Panel-Based IVD Testing Market, By End User, Revenue Distribution, 2025 (%) [Emergency/UC, Hospital, Independent/Reference, OTC/Retail, Physician Office]
  • Hospital Lab
    • Table 9-13: Hospital Lab IVD Panel-Based Test Revenue, 2025-2030 ($ million)
  • Emergency (ER)/Urgent Care (UC)
    • Table 9-14: Emergency (ER)/Urgent Care (UC) IVD Panel-Based Test Revenue, 2025-2030 ($ million)
  • Independent/Reference Lab
    • Table 9-15: Independent/Reference Lab IVD Panel-Based Test Revenue, 2025-2030 ($ million)
  • Physician Office
    • Table 9-16: Physician Office IVD Panel-Based Test Revenue, 2025-2030 ($ million)
  • OTC/Retail/Others
    • Table 9-17: OTC/Retail/Other IVD Panel-Based Test Revenue, 2025-2030 ($ million)
• Market by Region
  • Figure 9-14: Total Panel-Based IVD Testing Market, By Geographic Region, 2020-2030 ($ million) [Asia Pacific, Europe, North America, RoW]
  • Figure 9-15: Total Panel-Based IVD Testing Market, By Geographic Region, Revenue Distribution, 2025 (%) [Asia Pacific, Europe, North America, RoW]
  • North America
    • Table 9-18: North America - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Figure 9-16: North America - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
  • Europe
    • Table 9-19: Europe - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Figure 9-17: Europe - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
  • Asia Pacific
    • Table 9-20: Asia Pacific - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Figure 9-18: Asia Pacific - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]
  • RoW
    • Table 9-21: Rest of World - IVD Panel-Based Test Revenue, 2025-2030 ($ million)
    • Figure 9-19: Rest of World - IVD Panel Market, 2020-2030 ($ million) [Anatomic Pathology, Core Lab, Immunoassay, Immunohematology, Molecular, POC]